Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model

Visigalli, I., Delai, S., Politi, L., Di Domenico, C., Cerri, F., Mrak, E., D'Isa, R., Ungaro, D., Stok, M., Sanvito, F., Mariani, E., Staszewsky, L., Godi, C., Russo, I., Cecere, F., del Carro, U., Rubinacci, A., Brambilla, Riccardo, Quattrini, A., Di Natale, P., Ponder, K., Naldini, L. and Biffi, A. 2010. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116 (24) , pp. 5130-5139. 10.1182/blood-2010-04-278234

Full text not available from this repository.

Abstract

Type I mucopolysaccharidosis (MPS I) is a lysosomal storage disorder caused by the deficiency of α-L-iduronidase, which results in glycosaminoglycan accumulation in tissues. Clinical manifestations include skeletal dysplasia, joint stiffness, visual and auditory defects, cardiac insufficiency, hepatosplenomegaly, and mental retardation (the last being present exclusively in the severe Hurler variant). The available treatments, enzyme-replacement therapy and hematopoietic stem cell (HSC) transplantation, can ameliorate most disease manifestations, but their outcome on skeletal and brain disease could be further improved. We demonstrate here that HSC gene therapy, based on lentiviral vectors, completely corrects disease manifestations in the mouse model. Of note, the therapeutic benefit provided by gene therapy on critical MPS I manifestations, such as neurologic and skeletal disease, greatly exceeds that exerted by HSC transplantation, the standard of care treatment for Hurler patients. Interestingly, therapeutic efficacy of HSC gene therapy is strictly dependent on the achievement of supranormal enzyme activity in the hematopoietic system of transplanted mice, which allows enzyme delivery to the brain and skeleton for disease correction. Overall, our data provide evidence of an efficacious treatment for MPS I Hurler patients, warranting future development toward clinical testing.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Subjects: Q Science > Q Science (General)
Publisher: American Society of Hematology
ISSN: 0006-4971
Last Modified: 04 Jun 2017 03:38
URI: http://orca.cf.ac.uk/id/eprint/24170

Citation Data

Cited 99 times in Google Scholar. View in Google Scholar

Cited 83 times in Scopus. View in Scopus. Powered By Scopus® Data

Cited 57 times in Web of Science. View in Web of Science.

Actions (repository staff only)

Edit Item Edit Item